Finance

Lists
DMRA:NASDAQ
Damora Therapeutics Inc
$29.60
+0.20%
(+0.060) 1D
Aug 11, 2:28:02 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DMRA...
Open
$29.89
High
$30.78
Low
$29.14
Mkt. cap
1.82B
Avg. vol.
486.68K
Volume
100.26K
52-wk high
$34.89
52-wk low
$16.50
EPS
-$141.43
Beta
1.47
Shares outstanding
61.55M
No. of employees
7
Open
$29.89
High
$30.78
Low
$29.14
Mkt. cap
1.82B
Avg. vol.
486.68K
Volume
100.26K
52-wk high
$34.89
52-wk low
$16.50
EPS
-$141.43
Beta
1.47
Shares outstanding
61.55M
No. of employees
7
News stories
From web sources and news partners
About Damora Therapeutics Inc
CEO-
Employees7
Founded2011
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Websitedamoratx.com
Analyst ratings
Based on 8 analysts giving stock ratings to DMRA in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for DMRA in the last 3 months.
Highest
Current $29.60
$51.00 (+72.30%)
Average
$44.43 (+50.10%)
Lowest
$40.00 (+35.14%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Nierengarten
Wedbush
Buy
Maintained
$40.00
+35.1%
08/11/2026
Brian Abrahams
RBC Capital
Buy
Maintained
$40.00
+35.1%
08/10/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$45.00
+52%
08/11/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$45.00
+52%
08/11/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
08/10/2026
Akash Tewari
Jefferies
Buy
Maintained
$50.00
+68.9%
08/11/2026
Bradley Canino
Guggenheim
Buy
Maintained
$40.00
+35.1%
06/15/2026
Andrew Berens
Leerink Partners
Buy
Maintained
$51.00
+72.3%
05/15/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Initiated
$46.00
+55.4%
03/25/2026
Michael Yee
UBS
Buy
Initiated
$45.00
+52%
02/17/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
1.46M
1.42M
23.32M
23.78M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.96M
1.74M
4.07M
7.03M
Operating expense
3.42M
3.16M
27.39M
30.81M
Total operating expenses
3.42M
3.16M
27.39M
30.81M
Operating income
-3.42M
-3.16M
-27.39M
-30.81M
Other non operating income
-
-
-
-
EBT including unusual items
-3.43M
-3.13M
-200.69M
-27.74M
EBT excluding unusual items
-3.43M
-3.13M
-26.38M
-27.74M
Income tax expense
4.00K
-
44.00K
42.00K
Effective tax rate
-0.12%
-
-0.02%
-0.15%
Other operating expenses
-
-
-
-
Net income
-3.44M
-3.13M
-200.74M
-27.78M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-0.62
Interest and investment income
50.00K
42.00K
1.00M
3.07M
Interest expense
-
-
-
-
Net interest expenses
50.00K
42.00K
1.00M
3.07M
Depreciation and amortization charges
-
-
-
-
EBITDA
-3.42M
-3.15M
-27.38M
-30.81M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps